Simcere Pharmaceutical Group Ltd
HKEX:2096

Watchlist Manager
Simcere Pharmaceutical Group Ltd Logo
Simcere Pharmaceutical Group Ltd
HKEX:2096
Watchlist
Price: 6.78 HKD 2.11%
Market Cap: 17.1B HKD
Have any thoughts about
Simcere Pharmaceutical Group Ltd?
Write Note

Simcere Pharmaceutical Group Ltd
Tax Provision

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Simcere Pharmaceutical Group Ltd
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Simcere Pharmaceutical Group Ltd
HKEX:2096
Tax Provision
-ÂĄ26.1m
CAGR 3-Years
43%
CAGR 5-Years
33%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Tax Provision
-ÂĄ488.7m
CAGR 3-Years
3%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Tax Provision
-ÂĄ554.6m
CAGR 3-Years
-10%
CAGR 5-Years
-19%
CAGR 10-Years
-25%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Tax Provision
-ÂĄ498.4m
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
-9%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Tax Provision
-ÂĄ637.7m
CAGR 3-Years
18%
CAGR 5-Years
-9%
CAGR 10-Years
-4%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Tax Provision
-ÂĄ11.5m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Simcere Pharmaceutical Group Ltd
Glance View

Market Cap
17.2B HKD
Industry
Pharmaceuticals

Simcere Pharmaceutical Group Ltd., established in China, navigates the complexities of the pharmaceutical industry with a focus on innovation and accessibility. Emerging as a dynamic player, Simcere embraces a strategy that marries research-driven innovation with pragmatic commercial practices. The company operates a diversified portfolio, prominently featuring pharmaceuticals dedicated to oncology, cardiovascular diseases, and the central nervous system. By maintaining a robust pipeline of new drug candidates while leveraging its existing catalog, Simcere adeptly navigates the challenges of the pharma landscape. Their dedication to research and development is evident, with substantial investment channeled towards creating proprietary medicines that aim to address unmet medical needs and improve patient outcomes. The path to profitability for Simcere hinges on its dual strategy of developing novel therapeutics and forming strategic partnerships. Simcere not only invests heavily in its proprietary R&D but also engages in collaborations with global pharmaceutical enterprises, thus expanding its reach and influence in the global market. The company adeptly manages a sophisticated supply chain to ensure its products are both widely distributed and affordable, adhering to high standards of regulatory compliance in various metropolises. This operational efficiency, coupled with the strategic alliances, allows Simcere to capture significant market share, driving top-line growth and reinforcing its reputation as an innovative leader in the pharmaceutical industry.

Intrinsic Value
10.61 HKD
Undervaluation 36%
Intrinsic Value
Price

See Also

What is Simcere Pharmaceutical Group Ltd's Tax Provision?
Tax Provision
-26.1m CNY

Based on the financial report for Dec 31, 2023, Simcere Pharmaceutical Group Ltd's Tax Provision amounts to -26.1m CNY.

What is Simcere Pharmaceutical Group Ltd's Tax Provision growth rate?
Tax Provision CAGR 5Y
33%

The average annual Tax Provision growth rates for Simcere Pharmaceutical Group Ltd have been 43% over the past three years , 33% over the past five years .

Back to Top